Passive/Active Immunization Against Hepatitis B

No differences in eventual immune-response rates were found between 325 subjects immunized passively/actively against hepatitis B and a control group of 108 subjects vaccinated only actively. The geometric mean titers of antibodies to hepatitis B surface antigen were nearly identical in controls and...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 150; no. 1; pp. 112 - 117
Main Authors Zachoval, Reinhart, Jilg, Wolfgang, Lorbeer, Bernd, Schmidt, Marion, Deinhardt, Friedrich
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.07.1984
University of Chicago Press
Subjects
Adult
Age Factors
Antibodies
Biological and medical sciences
Female
Half-Life
Hepatitis antigens
Hepatitis B
Hepatitis B - immunology
Hepatitis B Antibodies - biosynthesis
Hepatitis B Surface Antigens - immunology
Hepatitis B Vaccines
Hepatitis B virus
Hepatitis B virus - immunology
Human viral diseases
Humans
Immune response
Immunization
Immunization, Passive - adverse effects
Immunoglobulins
Infections
Infectious diseases
Male
Medical sciences
Original Articles
Sex Factors
Time Factors
Vaccination
Vaccination - adverse effects
Viral diseases
Viral hepatitis
Viral Vaccines - immunology
Infection
Viral hepatitis B
Immunoprophylaxis
Passive immunization
Viral disease
Active immunization
Online AccessGet full text

Cover

More Information
Summary:No differences in eventual immune-response rates were found between 325 subjects immunized passively/actively against hepatitis B and a control group of 108 subjects vaccinated only actively. The geometric mean titers of antibodies to hepatitis B surface antigen were nearly identical in controls and in a group of 87 individuals immunized passively/actively with the same vaccine lot. Lower geometric mean titers of antibodies to hepatitis B surface antigen were seen in 238 individuals who were vaccinated passively/actively with a different vaccine lot, a difference that may be explained by a somewhat lower immunogenicity in this particular lot. The mean half-life of hepatitis B immunoglobulin was calculated as 24.8 days, and in ∼90% of vaccinees 300,000 mIU of hepatitis B immunoglobulin provided protection until an active immune response had developed.
Bibliography:Informed consent was obtained from the participants in this study or from their guardians and guidelines for human experimentation of the University of Munich were followed in the conduct of this study.
istex:87D121E866D734C1109A28D56F70CA4E8530AC20
ark:/67375/HXZ-X68NKFW5-X
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/150.1.112